Captrust Financial Advisors Clearside Biomedical, Inc. Transaction History
Captrust Financial Advisors
- $43.1 Billion
- Q2 2025
A detailed history of Captrust Financial Advisors transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 87,000 shares of CLSD stock, worth $343,650. This represents 0.0% of its overall portfolio holdings.
Number of Shares
87,000
Previous 87,000
-0.0%
Holding current value
$343,650
Previous $80,000
13.75%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CLSD
# of Institutions
12Shares Held
3.33MCall Options Held
0Put Options Held
0-
Act Capital Management, LLC Wayne, PA2.2MShares$8.68 Million3.43% of portfolio
-
Black Rock Inc. New York, NY798KShares$3.15 Million0.0% of portfolio
-
Carmignac Gestion Paris, I0101KShares$397,1960.01% of portfolio
-
Northeast Financial Consultants Inc Westport, CT93KShares$367,3500.0% of portfolio
-
Credit Suisse Ag Zurich, V825KShares$98,7500.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $238M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...